#China #Chengdu #radiopharmaceuticals #Full-Life Technologies #Junson Capital

Full-Life Technologies' Major Financing Initiative

In a significant development for the field of radiotherapeutics, Full-Life Technologies has successfully secured $77 million in financing to enhance its radiopharmaceutical pipeline and manufacturing capabilities. This funding round, finalized on September 29, 2025, consists of a $50 million Series C equity financing and an additional $27 million in debt financing.

Strengthening a Promising Pipeline

The financing will primarily support the expansion of Full-Life's global radiopharmaceutical pipeline, emphasizing its manufacturing facilities in Belgium. Since its inception in 2021, the company has attracted nearly $200 million in diverse funding sources, including equity, debt, and strategic partnerships.

Leadership and Investment Confidence

This round was spearheaded by Junson Capital, alongside newly introduced investors such as Lapam Capital and Plaisance, in tandem with existing stakeholders including Chengwei Capital and Gordian Ventures. Notably, Junson Capital has been a consistent backer since the company’s Series A financing round in 2022.

Wei Shen, the Head of Principal Investment at Junson, commended Full-Life for its strategic vision. He emphasized the company’s drive to meet the growing demand for radionuclide drug conjugates (RDC), particularly in oncology treatments that utilize alpha emitters such as 225Ac. The innate challenges of short supply in this sector underscore the company's significant role in advancing treatments.

Future Directions and Goals

Julie Wu, Full-Life's President and CFO, reflected on the investor backing as a strong vote of confidence in their operational strategy and achievements over the past four years. The funds obtained will enhance various initiatives, including:

• - Completion of a global Phase I clinical trial for their leading asset, [225AC]AC-FL-020.
• - Advance development into further clinical studies.
• - Facilitate new IND filings worldwide.
• - Finalize construction of a Good Manufacturing Practices (GMP) facility in Belgium, essential for maintaining regulatory standards and production quality.

About Full-Life Technologies

Full-Life Technologies operates as a fully-integrated clinical-stage radiotherapeutics company, boasting a presence in Belgium, Germany, and China. Their mission revolves around owning the entire value chain in radiopharmaceutical research—from development to commercialization—to deliver significant clinical benefits to patients. The company is driven by a dynamic team of entrepreneurs and seasoned scientists proficient in the life sciences, poised to address the fundamental challenges facing the radiopharmaceutical field.

As this significant funding initiative unfolds, Full-Life technologies is set to reinforce its role as a leader in innovating solutions targeting critical health challenges associated with cancer treatment. With the growing importance of personalized medicine, the company’s forward trajectory appears promising and essential.